您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > 8-Methoxypsoralen
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
8-Methoxypsoralen
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
8-Methoxypsoralen图片
CAS NO:298-81-7
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
20mg电议

产品介绍
8-Methoxypsoralen (8-Methoxypsoralen) 是一种有效的 CYP(细胞色素 P-450)三环呋喃香豆素自杀抑制剂,是一种用于治疗银屑病、湿疹、白癜风和一些皮肤淋巴瘤以及将皮肤暴露在阳光下的药物。
Cas No.298-81-7
别名甲氧沙林; 8-Methoxypsoralen; Xanthotoxin; 8-MOP
化学名9-methoxyfuro[3,2-g]chromen-7-one
Canonical SMILESCOC1=C2C(=CC3=C1OC=C3)C=CC(=O)O2
分子式C12H8O4
分子量216.19
溶解度≥ 6.5mg/mL in DMSO
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Methoxsalen (8-Methoxypsoralen) is a potent tricyclic furocoumarin suicide inhibitor of CYP (cytochrome P-450), is an agent used to treat psoriasis, eczema, vitiligo and some cutaneous Lymphomas in conjunction with exposing the skin to sunlight.Target: CYP (cytochrome P-450)Methoxsalen is a drug used to treat psoriasis, eczema, vitiligo, and some cutaneous lymphomas in conjunction with exposing the skin to UVA light from lamps or sunlight. Methoxsalen modifies the way skin cells receive the UVA radiation, allegedly clearing up the disease. The dosage comes in 10 mg tablets, which are taken in the amount of 30 mg 75 minutes before a PUVA (psoralen + UVA) light treatment. Chemically, methoxsalen belongs to a class of organic natural molecules known asfuranocoumarins. They consist of coumarin annulated with furan.Administration of intra peritoneal (ip) methoxsalen significantly increased nicotine's Cmax, prolonged the plasma half-life (fourfold decrease) of nicotine, and increased its area under the curve (AUC) compared with ip vehicle treatment. Methoxsalen pretreatment prolonged the duration of nicotine-induced antinociception and hypothermia (15mg/kg, po) for periods up to 6- and 24-hr postnicotine administration, respectively.

References:
[1]. Alsharari SD, et al. Pharmacokinetic and Pharmacodynamics Studies of Nicotine After Oral Administration in Mice: Effects of Methoxsalen, a CYP2A5/6 Inhibitor. Nicotine Tob Res. 2014 Jan;16(1):18-25.